Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
NAMS compared with AURA: revenue, margins and what each company keeps, and the suppliers and customers both name
NAMS
NewAmsterdam Pharma Co N.V.
Change
Mkt cap
Revenue
Revenue
AURA
Aura Biosciences, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
NAMS
NewAmsterdam Pharma Co N.V.
vs
AURA
Aura Biosciences, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
NAMS: latest quarter is a loss; flow not drawable. AURA: latest quarter not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
No disclosed counterparties: NAMS, AURA.
Role chip = supplier or customer
Source: SEC EDGAR
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
NAMS, solid
AURA, dashed
NAMS
NewAmsterdam Pharma Co N.V.
Change
20.22
▲
+0.80%
Mkt cap
$2.4B
Revenue
$4M
Q2 FY26
Revenue
$23M
FY25
AURA
Aura Biosciences, Inc.
Change
5.94
▼
−3.19%
Regular session
Sep 2 '83
Mkt cap
$636.7M
Revenue
—
Revenue
—
vs
Compare
Regular session
Sep 2 '83
NAMS
NewAmsterdam Pharma Co N.V.
vs
AURA
Aura Biosciences, Inc.
20.22
▲
+0.80%
Price
5.94
▼
−3.19%
$2.4B
Mkt cap
$636.7M
Q2 FY26
$4M
Revenue
—
FY25
$23M
Revenue
—
Change
Change
NAMS
20.22
▲
+0.80%
vs
AURA
5.94
▼
−3.19%
Regular session
Sep 2 '83